Arsenic Trioxide: Pharmacological Applications

Authors

  • German Madrigal Redondo Universidad de Costa Rica https://orcid.org/0000-0002-9856-4044
  • María Fernanda Rojas Salas Universidad de Costa Rica
  • Rolando Vargas Zúñiga Universidad de Costa Rica https://orcid.org/0000-0002-5707-4188
  • Daniela González Corrales Universidad de Costa Rica
  • Celeste Ortega Monge Universidad de Costa Rica
  • Pamela Ceciliano Porras Universidad de Costa Rica
  • Mariana Cerdas Delgado Universidad de Costa Rica
  • Jeison Montero Rivera Universidad de Costa Rica

DOI:

https://doi.org/10.17533/udea.vitae.v30n1a349001

Keywords:

arsenic trioxide, pharmacological alternative, cancer, carcinoma

Abstract

Background: Arsenic trioxide is a chemical compound that has been used as a treatment for various diseases. Despite being potentially toxic, this compound has been used as a therapy to treat Acute Myeloid Leukemia and is being investigated as a possible treatment for different types of cancer.
Objectives: The present review aims to describe the use and studies reported in the literature of Arsenic Trioxide as a possible therapeutic agent for Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Chronic Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Hepatocellular Carcinoma, Lung Cancer, Neuroblastoma, Breast Cancer, Aplastic Hepatitis C, and HIV-1.
Methods: A systematic review was conducted using databases (Elsevier, Google Scholar, PubMed) to compile documents published before December 2023.
Results: Multiple pharmacological applications of arsenic trioxide have been reported to treat acute and chronic myeloid leukemia. Arsenic trioxide has been shown to inhibit angiogenesis, which helps treat multiple myeloma. Several studies have shown and suggested the effectiveness of arsenic trioxide as a treatment of hepatocellular carcinoma, lung cancer, neuroblastoma, prostate cancer, breast cancer, aplastic anemia, hepatitis C, and HIV-1.
Conclusion: Despite potentially toxic effects, Arsenic compounds are therapeutic agents for multiple diseases, from syphilis to cancer. In recent years, more efficient ways have been investigated to deliver and find the specific dose to treat the disease, causing the fewest possible adverse effects.

|Abstract
= 462 veces | PDF
= 289 veces| | HTML
= 3 veces|

Downloads

Download data is not yet available.

References

Padrón C, Espinosa E, Losada R, Ávila O, Hernández P. Trióxido de arsénico: una nueva luz en el tratamiento de la leucemia promielocítica. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2008; 24(2): 1-9. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892008000200001

Antman K. Introduction: The History of Arsenic Trioxide in Cancer Therapy. The Oncologist. 2001; 6(2): 1-2. DOI: https://doi.org/10.1634/theoncologist.6-suppl_2-1

Hoonjan M, Jadhav V, Bhatt P. Arsenic trioxide: insights into its evolution to an anticancer agent. JBIC. 2018; 23(3): 313–329. DOI: https://doi.org/10.1007/s00775-018-1537-9

Suárez C, Noa Y, Rodríguez I, Hernández G, de la Uz Ruesga B. Tratamiento con trióxido de arsénico en pacientes con leucemia promielocítica aguda. MEDISAN [Internet]. 2014; 18(1): 25-33. Available from: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=47402

Mejía J, Núñez J, Fajardo A, Rodríguez M, Martín J, Duarte D, et al. Epidemiología descriptiva de la leucemia mieloide aguda (LMA) en niños residentes de la Ciudad de México: reporte del Grupo Mexicano Interinstitucional para la Identificación de las Causas de la Leucemia en Niños. Gac Med Mex [Internet]. 2016; 152(S2): 66-77. Available from: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=68755

Sanz M, Fenaux P, Tallman M, Estey, E, Löwenberg B, Naoe T, Lengfelde, E, Döhener H, Burnett A, Chen Sai-Juan, Mathewa V, Iland H, Rego E, Kantarjian H, Adés L, Avvisati G, Montesinoes P, Platzbecker U, Ravandi F, Russell N, Lo-Coco F. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019; 133(15): 1630-1643. DOI: https://doi.org/10.1182/blood-2019-01-894980

Mejía-Buriticá L, Torres-Hernández JD, Vásquez G de J. Leucemia promielocítica aguda. Estado del arte. Iatreia. 2020; 34(1): 42-53. DOI: https://doi.org/10.17533/udea.iatreia.76

Watts J, Tallman M. Acute promyelocytic leukemia: What is the new standard of care?. Blood Rev. 2014; 28(5): 205-212. DOI: https://doi.org/10.1016/j.blre.2014.07.001

Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017; 129(10): 1275-1283. DOI: https://doi.org/10.1182/blood-2016-09-736686

European Medicines Agency. Science Medicines Health, Trisenox. https://www.ema.europa.eu/en/medicines/human/EPAR/trisenox 2019.

Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. N Engl J Med. 2013; 369(2): 111-121. DOI: https://doi.org/10.1056/nejmoa1300874

Moreno M, Lassaletta A, García A, Sevilla J, Madero L. Tratamiento con trióxido de arsénico en paciente con recaída de leucemia promielocítica aguda. Anales de Pediatría. 2010; 73(1): 39-41. DOI: https://doi.org/10.1016/j.anpedi.2010.04.010

Aristizábal J, Chandia M, del Cañizo M.C, Sánchez-Guijo F. Microambiente medular en la leucemia mieloide crónica: su relación con la enfermedad y la respuesta al tratamiento. Rev. méd. Chile. 2014; 142(5): 599-605. DOI: http://dx.doi.org/10.4067/S0034-98872014000500008

Goldman J, Melo J. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med. 2003. 349(15): 1451-1464. DOI: http://dx.doi.org/10.1056/NEJMra020777

El Eit RM, Iskandarani AN, Saliba JL, Jabbour MN, Mahfouz RA, Bitar NMA, et al. Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha: Arsenic and interferon targets CML initiating cells activity. Int J Cancer. 2014; 134(4): 988-996. DOI: https://doi.org/10.1002/ijc.28427

Luo X, Feng M, Zhu X, Li Y, Fei J, Zhang Y. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia. Hemat. 2013;18(6), 334-340. DOI: https://doi.org/10.1179/1607845413Y.0000000083.

Peng Y, Zhao Z, Liu T, Li X, Hu X, Wei X, et al. Smart Human‐Serum‐Albumin–As2O3 Nanodrug with Self‐Amplified Folate Receptor‐Targeting Ability for Chronic Myeloid Leukemia Treatment. Angewandte Chemie International Edition. 2017; 56(36): 10845-10849. DOI: https://doi.org/10.1002/anie.201701366

Guo Z, Meng M, Geng S, Du Z, Zheng Y, Yao J, Et al. The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia. JEthnopharmacol. 2017; 196: 29-38. Doi: https://doi.org/10.1016/j.jep.2016.12.010

Philips S, Hildenbrand Z, Oravecz-Wilson K, Foley S, Mgbemena V, Ross T, Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells. Oncogene. 2014; 33: 5379-5390. DOI: https://doi.org/10.1038/onc.2013.484

Iland H, Collins M, Bradstock K, Supple S, Catalano A, Hertzberg M, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015; 2(9): e357-e366. Doi: https://doi.org/10.1016/S2352-3026(15)00115-5

Colvin T, Vachhani P, Sait S, Neppalli V, Wang E. All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis. Leuk Res Rep. 2018; 10: 16-19. DOI: https://doi.org/10.1016/j.lrr.2018.07.002

Alvarado M, Álvarez J, Anaya I, De la Peña A, García L, Hernández E, et al. Primer Consenso Nacional de Mieloma Múltiple por Hematólogos del ISSSTE. RevHematol Mex [Internet]. 2015; 16 (4), 306-332. Available from: https://www.medigraphic.com/pdfs/hematologia/re-2015/re154i.pdf

Nikhil C. Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma. The Oncologist. 2001; 6 (2), 17-21. DOI: https://doi.org/10.1634/theoncologist.6-suppl_2-17

He X, Yang K, Chen P, Liu B, Zhang Y, Wang F, Guo Z, Liu X, Lou J, Chen H. Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. Onco Targets Ther. 2014; (7), 1593-1599. DOI: https://doi.org/10.2147/OTT.S67165

Hu J, Huang X, Hong X, Lu Q, Zhu X. Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway. Cancer Cell International. 2013;13 (25): 1-6. DOI: https://doi.org/10.1186/1475-2867-13-25

Forner A, Ayuso C, Real M, Sastre J, Robles R, Sangro B, et al. Diagnóstico y tratamiento del carcinoma hepatocelular. Med Clin. 2009; 132(7): 272-287. DOI: https://doi.org/10.1016/j.medcli.2008.11.024

Martínez J, Lledó J, Aicart-Ramos M, Mateos B, Albillos A. Carcinoma hepatocelular. Medicine-Programa de Formación Médica Continuada Acreditado. 2016; 12(12), 683-692. DOI: https://doi.org/10.1016/j.med.2016.05.022

He L, Xu Q, Chen L, Chen R. A Meta-Analysis of Arsenic Trioxide Combined with Transcatheter Arterial Chemoembolization for Treatment of Primary Hepatic Carcinoma. Evid Based Complement Alternat Med. 2016; 3428370. DOI: https://doi.org/10.1155/2016/3428370

Liu B, Huang J, Li Y, Hu B, He X, Zhao, W, et al. Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial. J Cancer Res Clin Oncol. 2015; 141(6): 1103–1108. DOI: https://doi.org/10.1007/s00432-014-1866-1

Lu W, Yang C, Du P, Zhang J, Zhang J. Effects of arsenic trioxide on the expression of ezrin in hepatocellular carcinoma. Medicine. 2017; 96(35), e7602. DOI: https://doi.org/10.1097/MD.0000000000007602

Pérez L, Rodríguez O, Morales Y, Amores A, Jaime M, Pérez A. Cáncer de pulmón: aspectos clínicos y diagnósticos en pacientes afectados del Policlínico “Marta Abreu”. Estudio de cinco años. Acta Médica del Centro [Internet]. 2017; 11(3): 49-56. Available from: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=73620

Walker A, Stevens, J, Ndebele K, Tchounwou P. Evaluation of Arsenic Trioxide Potential for Lung Cancer Treatment: Assessment of Apoptotic Mechanisms and Oxidative Damage. J Cancer Sci Ther. 2016; 8(1): 1–9. DOI: https://doi.org/10.4172/1948-5956.1000379

Dumba, M, Jawad N, McHugh K. Neuroblastoma and nephroblastoma: a radiological review. Cancer imaging. 2015; 15(1):5. DOI: https://doi.org/10.1186/s40644-015-0040-6

Tsubota S, Kadomatsu K. Origin and initiation mechanisms of neuroblastoma. Cell Tissue Res. 2018; 372(2): 211-221. DOI: https://doi.org/10.1007/s00441-018-2796-z

Qi K, Li Y, Huang K, Xiong X, Chuchu F, Zhang C, Weng W. Pre-application of arsenic trioxide may potentiate cytotoxic effects of vinorelbine/docetaxel on neuroblastoma SK-N-SH cells. Biomedicine & Pharmacotherapy. 2019; 113: 108665. DOI: https://doi.org/10.1016/j.biopha.2019.108665

Ruiz A, Pérez J, Cruz Y, González L. Actualización sobre cáncer de próstata. Correo Científico Médico [Internet]. 2017; 21(3): 876-887. Available from: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=73979

Dilda P, Hogg P. Arsenical-based cancer drugs. Cancer Treat Rev. 2007; 33(6), 542–564. DOI: https://doi.org/10.1016/j.ctrv.2007.05.001

Chiu HW, Chen YA, Ho SY, Wang YJ. Arsenic Trioxide Enhances the Radiation Sensitivity of Androgen-Dependent and -Independent Human Prostate Cancer Cells. PLoS ONE. 2012; 7(2): e31579. DOI: https://doi.org/10.1371/journal.pone.0031579

Hayes DF, Lippman ME. Cáncer de mama. Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J(Eds.), Harrison. Principios de Medicina Interna, 20e. McGraw-Hill; 2018.

Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, et al. Arsenic Trioxide and Breast Cancer: Analysis of the Apoptotic, Differentiative and Immunomodulatory Effects. Breast Cancer Res Treat. mayo de 2002;73(1):61-73. DOI: https://doi.org/10.1023/a:1015272401822

Chen G, Guan L, Hu W, Wang Z. Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells. Anticancer Res [Internet]. 2002; 22(2A): 633-638. Available from: https://pubmed.ncbi.nlm.nih.gov/12014631/

Lai Y-L, Chang H-H, Huang M-J, Chang K-H, Su W-H, Chen H-W, et al. Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer a pilot study. Anticancer Drugs. 2003; 14(10): 825-8. DOI: https://doi.org/10.1097/00001813-200311000-00008

Cantú O. Anemia aplásica. In: Pérez J, Almaguer D. eds. Hematología. La sangre y sus enfermedades, 4e. McGraw-Hill; 2016. Accessed November 02, 2020.

Zhao J, Song Y, Liu L, Yang S, Fang B. Effect of arsenic trioxide on the Tregs ratio and the levels of IFN-γ, IL-4, IL-17 and TGF-β1 in the peripheral blood of severe aplastic anemia patients. Medicine (Baltimore). 2020; 99(26): e20630. DOI: https://doi.org/10.1097/MD.0000000000020630

Cheng H, Liu S, Li W, Zhao X, Cheng M, Qiu L et al. Arsenic trioxide regulates adipogenic and osteogenic differentiation in bone marrow MSCs of aplastic anemia patients through BMP4 gene, Acta Biochimica et Biophysica Sinica. 2015; 47(9): 673-679. DOI: https://doi.org/10.1093/abbs/gmv065

Li N, Song Y, Zhou J, Fang B. Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia. J Hematol Oncol. 2015; 5:61. DOI: https://doi.org/10.1186/1756-8722-5-61

Riedel S, Hobden JA, Miller S, Morse SA, Mietzner TA, Detrick B, Mitchell TG, Sakanari JA, Hotez P, Mejia R. Microbiología Médica [Internet]. 28e. McGraw-Hill; 2020. Available from: https://accessmedicina-mhmedical-com.ezproxy.sibdi.ucr.ac.cr/content.aspx?bookid=2955&sectionid=250836470

Hwang D, Tsa, Y, Lee J, Huang K, Lin R, Ho C, et al. Inhibition of Hepatitis C Virus Replication by Arsenic Trioxide. Antimicrobial Agents and Chemotherapy. 2004; 48 (8), 2876–2882. DOI: https://doi.org/10.1128/AAC.48.8.2876-2882.2004

Lewis W, Currie PF. HIV/AIDS AND THE CARDIOVASCULAR SYSTEM. In: Fuster V, Harrington RA, Narula J, Eapen ZJ. eds. Hurst's The Heart, 14e New York, NY: McGraw-Hill; 2017. Available from: http://accessmedicine.mhmedical.com.ezproxy.sibdi.ucr.ac.cr:2048/content.aspx?bookid=2046&sectionid=176566883.

Wang Q, Jiang Y, Naranmandura H. Therapeutic Strategy of Arsenic Trioxide in the Fight Against Cancers and Other Diseases. Metallomics. 2020; 12(3): 317-462. 10.1039.C9MT00308H–. DOI: https://doi.org/10.1039/c9mt00308h

Yang Q, Feng F, Li P, Pan E, Wu C, He Y, Zhang F, Zhao J, Li R, Feng L, Hu F, Li L, Zou H, Cai W, Lehner T, Sun C, Chen L. Arsenic Trioxide Impacts Viral Latency and Delays Viral Rebound after Termination of ART in Chronically SIV-Infected Macaque. Advanced Science. 2019; 6(13):1900319. DOI: https://doi.org/10.1002/advs.201900319

Mora G, Espinosa D, Casas C. Caracterización clínica de los pacientes con síndrome mielodisplásico. Acta Médica Colomb. 2016; 41(1): 36-41. DOI: https://doi.org/10.36104/amc.2016.538

Vey N, Bosly A, Guerci A, Feremans W, Dombret H, Dreyfus F, et al. Arsenic Trioxide in Patients with Myelodysplastic Syndromes: A Phase II Multicenter Study. J Clin Oncol. 2006; 24(16):2465-71. DOI: https://doi.org/10.1200/JCO.2005.03.9503

Emadi A, Gore SD. Arsenic trioxide — An old drug rediscovered. Blood Rev. 2010; 24(4-5):191-9. DOI: https://doi.org/10.1016/j.blre.2010.04.001

Fang S, Wan X, Zou X, Sun S, Hao X, Liang C, et al. Arsenic trioxide induces macrophage autophagy and atheroprotection by regulating ROS-dependent TFEB nuclear translocation and AKT/mTOR pathway. Cell Death Dis. 2021; 12(1):88. DOI: https://doi.org/10.1038/s41419-020-03357-1

Wang QQ, Hua HY, Naranmandura H, Zhu H-H. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia. Toxicol Appl Pharmacol. 2020;409. DOI: https://doi.org/10.1016/j.taap.2020.115299

Zhang P. On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia. Leuk Res Reports. 2017; 7:29–32. DOI: https://doi.org/10.1016/j.lrr.2017.03.001

Arsenic Trioxide

Downloads

Published

20-04-2023

How to Cite

Madrigal Redondo, G., Rojas Salas, M. F., Vargas Zúñiga, R., González Corrales, D., Ortega Monge, C., Ceciliano Porras, P., Cerdas Delgado, M., & Montero Rivera, J. (2023). Arsenic Trioxide: Pharmacological Applications. Vitae, 30(1). https://doi.org/10.17533/udea.vitae.v30n1a349001

Issue

Vol. 30 No. 1 (2023)

Section

Reviews

License

Copyright (c) 2023 German Madrigal Redondo, María Fernanda Rojas Salas, Rolando Vargas Zúñiga, Daniela González Corrales, Celeste Ortega Monge, Pamela Ceciliano Porras, Mariana Cerdas Delgado, Jeison Montero Rivera

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright Notice and Open Access Statement

The Journal Vitae works under the Open Access license, and the published manuscripts remain available for the public, both on the Journal's website and in databases, under the Creative Commons license, "Noncommercial Attribution" and "Share alike" systems, adopted in Colombia. Hence, when the authors agree to publish in the Journal Vitae, they will not have the right to economic retributions on publications and reproductions through different diffusion media. The documents are freely available to the internet public, permitting users to read, download, copy, distribute, print, search, or link to the full texts and pass them as data to software. The only constraint on reproduction and distribution, should be to give authors control over the integrity of their work and the right to be appropriately acknowledged and cited.

Authors declare that:

  1. They are the intellectual property owners and are responsible for all the information stated in the article.

  2. This manuscript has not been submitted or published in other printed or digital media. They accept the responsibility for the judgments, opinions, and points of view expressed in the published article and, therefore, they exonerate Universidad de Antioquia and Journal Vitae from any process.

  3. They exempt Universidad de Antioquia and Journal Vitae from settling conflicts or disputes related to the authorship of the referred article.

  4. They accept the revision of the original manuscript by suitable personnel, and they bind themselves to perform the corrections appointed or suggested by the assessors.

  5. Therefore, they know the editorial process and will not bind the Editorial Board of the Journal to assume any obligations regarding the volume and issue in which the article is published.

  6. They transfer the rights of publication, reprinting, and distribution of the article from the moment of its approval, in print and digital format, without the right to economic rewards, and under the licensing conditions considered relevant by Journal Vitae.

  7. They fully authorize Universidad de Antioquia and Journal Vitae to submit the published material to the diverse databases and indexing systems where the Journal can be found to comply with the requirements of the regulatory authorities to maintain the national classification of journals.

  8. They will assume the article publication costs established for the current issue, and they will make the payment as soon as they are informed about the volume and the issue in which the final version of the article is published.

  9. After the article is published, you can share digital or printed copies in a noncommercial manner. You will be able to use the paper in your institution or company for educational or research purposes, including the use in course programs.

Conflict of interest: Authors are responsible for recognizing and disclosing any financial or other benefits that could be perceived to bias their work, acknowledging all financial support and any personal connections with potential sponsors. Examples of such conflicts include receiving research funds or honoraria, serving on advisory boards, stock ownership, or employment and consulting arrangements. Authors without such connections should clearly state that they have no financial support or personal relationships that could be perceived to bias their work. All conflicts of interest should be disclosed on the author's identification page of the manuscript.

Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)